SCHEMBL14722808

SCHEMBL14722808

COc1cc2c(cc1OC)CN(CCCCNC(=O)c1ccc3ccccc3c1)CC2

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 13/20 0.90
DRD4 P21917 11/20 0.90
DRD2 P14416 8/20 0.90
DRD1 P21728 7/20 0.90
ABCB1 P08183 1/20 0.67
ABCG2 Q9UNQ0 1/20 0.67
HTR1A P08908 4/20 0.66
ADRA2A P08913 4/20 0.66
ADRA1D P25100 2/20 0.66
HTR2A P28223 2/20 0.66
HTR2C P28335 2/20 0.66
ADRA1A P35348 2/20 0.66
ADRA1B P35368 2/20 0.66
HTR2B P41595 2/20 0.66
MEN1 O00255 1/20 0.66
LMNA P02545 1/20 0.66
TP53 P04637 1/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
CYP2D6 P10635 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14721849 0.89 DRD3 (0.79) DRD3DRD4DRD2DRD1TMEM97
SCHEMBL14720483 0.87 HRH4 (0.74) DRD3DRD4DRD2DRD1ADRA1A
SCHEMBL8808167 0.84 ABCG2 (0.88) DRD3DRD4DRD2DRD1ABCB1
SCHEMBL8809186 0.83 ABCG2 (0.78) DRD3DRD4DRD2DRD1ABCB1
SCHEMBL12123762 0.82 ALDH1A1 (0.74) DRD3DRD4DRD2DRD1ABCB1
SCHEMBL8812802 0.80 ABCG2 (1.00) ABCB1ABCG2
Bp-897 SCHEMBL2125882 0.80 DRD2 (1.00) DRD3DRD4DRD2DRD1HTR1A
Bp-897 SCHEMBL30027453 0.80 DRD2 (1.00) DRD3DRD4DRD2DRD1HTR1A
Bp-897 SCHEMBL29382551 0.80 DRD2 (1.00) DRD3DRD4DRD2DRD1HTR1A
SCHEMBL8285661 0.79 SIGMAR1 (1.00) DRD3DRD4DRD2TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 US disclosed
CN-107260726-A Composition and method for treating nerve degenerative diseases 考格尼申治疗股份有限公司 2017-10-20 CN disclosed
US-20140378460-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2014-12-25 US disclosed
CN-104053436-A Compositions and methods for treating neurodegenerative diseases COGNITION THERAPEUTICS INC 2014-09-17 CN disclosed
EP-2747768-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE Cognition Therapeutics, Inc. (US) 2014-07-02 EP disclosed
WO-2013029060-A2 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378460-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 DRD3 475/4885DRD4 533/4885DRD2 164/4885
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 DRD3 475/4885DRD4 533/4885DRD2 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.